FirstWord: Market Research Reports

... leaders in FirstView’s NPS+ Cancer Pain 2017 (EU5). Based on a survey of 150 EU5-based medical oncologists, the report builds on the respected net promoter score (NPS) to compare ... NPS+ Cancer Pain Management 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn How satisfied doctors are with cancer pain ...

... widespread dissatisfaction among doctors Neurologists in the EU5 countries are not happy with available Parkinson’s disease treatments, and it shows. According to our survey ... Issues NPS+ Parkinson’s Disease 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn: How satisfied doctors are with Parkinson’s disease ...

... marketers and market access specialists, NPS+ Renal Cell Carcinoma brings focus and clarity for 8 leading RCC treatments. See not only ... and your competitors’ offerings. Get Answers to Key Questions About RCC Treatments Afinitor (everolimus): Which three key messages have made ... Important Brand Loyalty Issues NPS+ Renal Cell Carcinoma (EU5) looks into the perceptions and views impacting RCC brand loyalty from the ...

... leader in FirstView’s NPS+ Cancer Pain 2017 (US). Based on a survey of 100 US-based medical oncologists, the report builds on the respected net promoter score (NPS) to compare ... 11th and 16th, 2017. Explore Important Brand Loyalty Issues NPS+ Cancer Pain Management 2017 (EU5) explores key issues affecting brand loyalty ...

... ’s NPS+ Parkinson’s Disease 2017 (US). Based on a survey of 100 US-based neurologists, the report builds on the respected net promoter score (NPS) to compare loyalty for 11 major Parkinson ... Issues NPS+ Parkinson’s Disease 2017 (US) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn How satisfied doctors are with Parkinson’s disease ...

... marketers and market access specialists, NPS+ Renal Cell Carcinoma brings focus and clarity for 9 leading US RCC treatments. See not only ... and your competitors’ offerings. Get Answers to Key Questions About RCC Treatments Afinitor (everolimus): Which two key messages are getting ... Important Brand Loyalty Issues NPS+ Renal Cell Carcinoma (US) looks into the perceptions and views impacting RCC brand loyalty from the ...

... of market access barriers on prescriptions for Psoriasis, HIV, Multiple Sclerosis, and Rheumatoid Arthritis The challenges for overcoming market access barriers in oncology and immunology Recommendations for overcoming market access barriers Key Benefits Understand how the biosimilar market has grown in 2016 ...

... new targeted asthma therapies emerge, is time running out for Xolair? Xolair’s unique position in the targeted asthma treatment market is under threat. Teva’s Cinqair and ... , and how they expect developers to differentiate their pipeline asthma antibodies in KOL Insight: Targeted Therapies in Asthma. Twelve US and European KOLs give their insight ...

... for medical affairs use Content Highlights KEY FUNCTIONS MEDICAL AFFAIRS Overarching objectives Medical affairs role as the bridge between company and stakeholders Key challenges for medical affairs Establishing and professionalising medical affairs Access ...

Which medical affairs team is losing out despite high performance and satisfaction scores? Compare the medical affairs teams for 12 major Asthma/COPD drugs head to head ... company has 3 of the top 5 teams. All that and more in Medical Affairs Reputations: Asthma/COPD. Based on a survey of 100 US pulmonologists, the report covers teams from ...

... with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). Some say novel therapies ... to evolve over the next five years in KOL Insight: Colorectal Cancer. You’ll get 12 North American and European KOLs’ candid thoughts on 6 recently marketed CRC treatments ...

... , and learn what your brand can do to regain lost share, in Market Access Impact: Myeloma (EU5). The report covers major brands from Amgen, BMS/AbbVie ... & Johnson) Exploring Important Market Access Issues Market Access Impact: Myeloma explores key issues affecting Myeloma drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... , and learn what your brand can do to regain lost share, in Market Access Impact: Myeloma (EU5). The report covers major brands from Amgen, BMS ... ; Takeda) Exploring Important Market Access Issues Market Access Impact: Myeloma explores key issues affecting Myeloma drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...

... 1st and 2nd place medical affairs team. Where does your team rank? Compare the medical affairs teams for 12 major Asthma/COPD drugs head to head ... services most teams need to improve. All that and more in Medical Affairs Reputations: Asthma/COPD. Based on a survey of 100 US pulmonologists, the report covers teams from ...

... detractors into promoters and, ultimately, improve market share? FirstView’s NPS+ Type 2 Diabetes Mellitus report assesses brand loyalty for 12 EU T2DM treatments. Before planning ... 5th and 12th, 2016. Explore Important Brand Loyalty Issues NPS+ Type 2 Diabetes Mellitus (US) explores key issues affecting brand loyalty for T2DM drug ...

... contracting, and higher proof of value. Orphan drug developers need to take seriously the issues payers face and Orphan Drug Market Access: Payer Insights is a “must read” report that shows how positively working with them will have real market access benefits ...

... of therapies Pharma can leverage digital health to enhance drug treatment and improve behaviour Pharma motivated to compete with tech giants leading digital health The future of pharma investment in digital health technology Regulatory climate for pharma investment in digital health ...

... immense – but finding the right path to follow is challenging. The Healthcare Internet of Things: A Network of Opportunities for All casts a candid eye over the ... Content Highlights Growing connectivity as momentum for the Internet-of-Things (IoT) Embracing the IoT in healthcare and pharma Key insights Key drivers of the ...

... UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs ... advantage. Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product ...

... options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus has ... report reveals candid insights about the HCV landscape from 12 KOLs in North America and Europe. You’ll learn which treatments KOLs have confidence ... advantage. Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product ...

... in FirstView NPS+ Rheumatoid Arthritis (EU5). Request sample pages Based on a survey of 150 rheumatologists, the report builds on the respected net promoter score (NPS), comparing brand ... ) Simponi (golimumab; Merck Sharpe & Dohme) A Report Based on Expert Knowledge NPS+ Rheumatoid Arthritis (EU5) explores key issues affecting brand loyalty for drug manufacturers ...

... in FirstView NPS+ Rheumatoid Arthritis (US). Request sample pages Based on a survey of 100 rheumatologists, the report builds on the respected net promoter score (NPS), comparing brand ... in FirstView NPS+ Rheumatoid Arthritis (US). Request sample pages Based on a survey of 100 rheumatologists, the report builds on the respected net promoter score (NPS), comparing brand ...

... of engagement? Ultimately, what makes doctors want to talk to Medical Science Liaisons (MSLs)? The Real Value of Medical Affairs covers both sides of the equation with ... to help ease the transition from trials into the real world? Know what is valued and what isn’t: MA may be one of the busiest ... , EVA Pharma for Pharmaceutical & Medical Appliances, Egypt. Medical Affairs Lead, Top 10 Pharma Company, UK. Associate Director Global Medical Affairs, Medical Education, Top 15 Pharma ...

... payer and industry opinion, What is Value in Healthcare? The payers’ definition identifies the critical elements of value for payers, reviews ways value is assessed and proposes ... expressed the names of contributors have been kept anonymous. Payers A healthcare professional working at the Italian Medicines Agency (AIFA) A Commissioning Pharmacist ...

... 3 rival brands managed small barrier-related gains? Which barriers have the biggest impact on market share? Find out in Market Access Impact: NSCLC. Request sample pages ... ) Exploring Important Market Access Issues Market Access Impact: NSCLC explores key issues affecting NSCLC drug manufacturers. You’ll learn: How barriers affect market access: What brands ...

... barriers related to market access affect slightly more prescriptions than any other barrier. One brand has a small perception problem: 15% ... Exploring Market Access Barriers Market Access Impact: NSCLC explores key issues affecting NSCLC drug manufacturers. You’ll learn: How barriers affect market access: ...

... Medical Affairs teams from branded players maintain dominance over biosimilars? Two medical affairs teams lead in the EU5 growth hormone deficiency (GHD) treatment ... ran. Find out what your team needs to do to pull ahead in Medical Affairs Reputations: GHD (EU5). Comparing teams for 7 major GHD treatments ...

Two Medical Affairs teams lead the market. Can your team learn from their success? Two medical affairs teams have the lead in the US growth hormone ... performance? Find out, and see how your team measures up, in Medical Affairs Reputations: GHD (US). Comparing teams for 7 major GHD treatments from Pfizer ...

... like? Ultimately, how can the commercial benefits of Big Data be realised? Powering Commercial Effectiveness Through Big Data and Analytics explores how Big Data is evolving beyond the patient ... Big Data demand a departmental focus or a company-wide cultural shift? Speed, agility, credibility: Are you responding fast enough to gain an advantage through Big ...

... to increase as orphan drug price continue to rise. How can industry proactively respond to demonstrate value and support pricing? Clinical trials: As the orphan drug market ... full potential of the orphan drug market Key Topics Explored The drivers of pharma and investor interest in the potential of orphan drugs are demonstrated, as the ...

... third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists ( ... ) Plus 18 more – download the full list now Sample of KOLS interviewed Dr. Silvio Inzucchi MD. Professor of Medicine, Yale University School of ...

... treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will Gazyva’s/Gazyvaro’s ... reveals candid insights about the CLL landscape from 12 KOLs in North America and Europe. You’ll learn which treatments KOLs consistently ...

... in T2DM medical affairs. Can the top two teams hold onto their lead? Two medical affairs teams lead in the EU5 type 2 diabetes mellitus (T2DM) market, but for how long? Competition is fierce ... how your team measures up, in Medical Affairs Reputations: T2DM (EU5). Comparing teams for 12 major T2DM drugs from AstraZeneca, Boehringer Ingelheim, Eli Lilly ...

... how your team measures up, in Medical Affairs Reputations: T2DM (US). Comparing teams for 11 major T2DM drugs from AstraZeneca, Boehringer Ingelheim, Eli Lilly ... need most? Insights into Medical Affairs Teams for These T2DM Treatments DPP-IV inhibitors: DPP-IV inhibitors Januvia (sitagliptin; Merck & Co.) Tradjenta ...

... highly competitive multiple sclerosis (MS) treatment market, prescription barriers helped 6 of the 10 brands we surveyed eke out narrow market ... Exploring Market Access Barriers Market Access Impact: MS explores key issues affecting MS drug manufacturers. You’ll learn: How barriers affect market access: What ...

... highly competitive multiple sclerosis (MS) treatment market, prescription barriers helped 5 of the 10 brands we surveyed eke out narrow market ... Exploring Market Access Barriers Market Access Impact: MS explores key issues affecting MS drug manufacturers. You’ll learn: How barriers affect market access: What ...

... exactly how MCM can be measured effectively and how ROI goals can be achieved. Measuring Marketing Channel Effectiveness: Improving the ROI of Multichannel Marketing makes compelling reading as it reveals insights and the successful strategies used by 13 pharmaceutical marketing experts. Based ...

... CheckMate-026 announcement, provides early KOL insight into the trial’s near-term market impact. Special Feature: KOLs weigh in on CheckMate-026 results ... positive NSCLC Rociletinib (CO-1686; Celgene Corporation/Clovis Oncology) ALK-positive NSCLC Brigatinib (AP26113; ARIAD) ALK and EGFR mutation-negative NSCLC ...

Patience Assistance Programmes: Achieving Stakeholder Buy in Patient Assistance Programmes (PAPs) help US patients financially and improve compliance, adherence and outcomes – what’s not to ... off the need for PAPs? Patient Groups: What advantages could Pharma gain by closer collaboration with patient groups in the design and ...

... for Market Access? The profile of Market Access (MA) departments is on the up. No longer simply existing as a ‘bolt on’ for other, more traditional activities, MA is pushing back the marketing boundaries ... Steve Turley, Managing Director, UCB Market Access Expert, European Pharma Company Market Access Expert, European Specialist Pharma Company Market Access Expert, US Pharma Company . ABOUT ...

... Understand the Forces Shaping the Biosimilars Market Commercialisation: Differentiation may be the key success factor for biosimilars. Discover the strategies manufacturers ... biosimilars in Europe shaped attitudes toward switching both treatment-naïve and established patients to biosimilars? Getting crowded: How will the market handle multiple biosimilars ...

... . This new report from FirstView, Market Access Impact: Asthma/COPD, assesses current barriers and their effects for 12 leading asthma/COPD drugs from GSK, Novartis, AstraZeneca ... Market Access Issues Market Access Impact: Asthma/COPD explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: Which brands are physicians prescribing for asthma/COPD ...

... . This new report from FirstView, Market Access Impact: Asthma/COPD, assesses current barriers and their effects for 12 leading asthma/COPD drugs from GSK, Novartis, AstraZeneca ... Market Access Issues Market Access Impact: Asthma/COPD explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: Which brands are physicians prescribing for asthma/COPD ...

Market access for orphan drugs: Can your company break through in emerging markets? Find out which emerging markets offer the best investment prospects for orphan drug ... America Market Access Director, Leading Orphan Drug Company International Marketing Director, Europe-based orphan drug manufacturer Market Access Director, Rare Cancers-focused Biopharmaceutical Company Orphan Disease ...

... digital health companies were interviewed: Adam Brickman: Director, Strategic Communications and Public Policy, Omada Health Markus Christen: Head of Global Development, Proteus Digital Health ... , Strategic Marketing – mid size pharmaceutical company Director, Digital Health – large pharmaceutical company Director, Digital Health – top 10 pharmaceutical company Senior Vice President – large ...

... finally map the patient journey—developing better, more targeted treatments by knowing when and how to get involved. But companies without the skills to harness ... sometimes millions of patients to understand what's really going on in terms of patient care…” Practical Advice for Harnessing Big Data Breaking down the patient journey: Understand the ...

... show medical affairs push is paying off for immunotherapies In the EU5 Melanoma treatment market, one brand’s medical affairs team ... Medical Affairs Reputations: Melanoma. Comparing teams for 8 major melanoma drugs head to head, the report reveals how oncologists rate them overall, and on 12 key medical affairs ...

... on medical affairs teams for up-to-date information they can use to make better treatment decisions. Does your team deliver? Find out in Medical Affairs Reputations: Melanoma. Comparing teams for 8 major melanoma drugs head to head, the report reveals how oncologists rate them overall, and on 12 key medical affairs services ...

... while needs remain unmet. Now payers are fighting back Payers have had it with the high cost of Multiple Sclerosis (MS) drugs and now they ... contain costs. Get the details in Payer Insight: Multiple Sclerosis. You’ll learn what drives treatment costs up, what payers are doing to bring them down, why ...

... satisfied with current growth hormone deficiency treatment options, with only one therapy showing a positive Net Promoter Score (NPS). In the US, GHD brands seem better ... Loyalty Issues NPS+ GHD (EU5) explores key issues affecting brand loyalty for growth hormone manufacturers. You’ll learn: How satisfied the growth hormone market is. How ...